Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 20;9(7):e17100.
doi: 10.1016/j.heliyon.2023.e17100. eCollection 2023 Jul.

Research trends in cholangiocarcinoma treatments during the last 3 decades

Kainan Lin  1   2 , Jiasheng Cao  1   2 , Haibo Chen  3 , Win Topatana  1   2 , Jingwei Cai  1   2 , Bin Zhang  1   2 , Jiahao Hu  1   2 , Renan Jin  1   2
Affiliations

Research trends in cholangiocarcinoma treatments during the last 3 decades

Kainan Lin et al. Heliyon. .

Erratum in

Abstract

Background: Over the past 30 years, numerous studies have focused on the treatment of cholangiocarcinoma (CCA), and these treatments have greatly evolved.

Objectives: To better understand the research trends, we evaluated the most influential publications and attempted to identify their characteristics using bibliometric methods.

Methods: The most influential publications were identified from the Clarivate Analytics Web of Science Core Collection database. The general characteristics of included papers were identified, and the research trends were explored via the bibliometric method.

Results: The average total number of citations for of the listed publications were 312 (range from 165 to 1922). The highest number of papers were published during period II (2001-2010, n = 50), followed by period III (2011-2020, n = 28), and period I (1991-2000, n = 22). The United States and Germany have made remarkable achievements in this field. Institutionally, Mayo Clinic and Memorial Sloan-Kettering Cancer Center were the leading institutions, with Blumgart and Zhu from the United States being the most influential authors. Close collaboration was established between the leading countries, institutions, and authors. The Annals of Surgery contributed the most to the papers with the highest total number of citations. Surgery predominated during period I (n = 14, 63.6%), with a gradual decline occurring during periods II (n = 19, 41.3%, P = 0.085) and period III (n = 3, 9.4%, P = 0.002). Contrastingly, the number of publications related to systemic therapy has increased significantly since period II and peaked in period III.

Conclusions: Surgery remains the most important treatment for CCA. However systemic therapy has become a research and clinical application hotspot. These findings will contribute to the translation of treatments for CCA and provide researchers with relevant research directions.

Keywords: Bibliometric analysis; Cholangiocarcinoma; Surgery; Systemic therapy; Targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Annual and cumulative number of publications on CCA management over the last 4 decades. CCA, Cholangiocarcinoma.
Fig. 2
Fig. 2
Annual and cumulative number of the 100 most cited papers over the last 3 decades.
Fig. 3
Fig. 3
National distribution of the 100 most cited papers.
Fig. 4
Fig. 4
The cooperation relationships among countries that published the 100 most cited papers.
Fig. 5
Fig. 5
The cooperation relationships of (A) institutions and (B) authors that have co-published more than 3 top-cited articles.
Fig. 6
Fig. 6
The cluster analysis of keywords of the 100 most cited papers.
Fig. 7
Fig. 7
Main topic, subtopic, and article type of the 100 most cited papers.
Fig. 8
Fig. 8
Research trends of different main topics over the last 3 decades.
See this image and copyright information in PMC

References

    1. Brindley P.J., et al. cholangiocarcinoma. Nat. Rev. Dis. Prim. 2021;7(1):65. - PMC - PubMed
    1. Sato K., et al. Cholangiocarcinoma: novel therapeutic targets. Expert Opin. Ther. Targets. 2020;24(4):345–357. - PMC - PubMed
    1. Khan S.A., Tavolari S., Brandi G. Cholangiocarcinoma: Epidemiology and risk factors. Liver Int. 2019;39(Suppl 1):19–31. - PubMed
    1. Cillo U., et al. Surgery for cholangiocarcinoma. Liver Int. 2019;39(Suppl 1):143–155. - PMC - PubMed
    1. Rizzo A., Brandi G. First-line chemotherapy in advanced biliary tract cancer ten years after the ABC-02 trial: "and yet it moves!". Cancer Treat Res Commun. 2021;27 - PubMed

LinkOut - more resources